Capsugel gets more manufacturing expertise with two-company deal

Amit Patel, president of Capsugel Dosage Form Solutions

Capsulemaker and drug formulation specialist Capsugel is adding to its manufacturing and broadening its dosing form capabilities with a deal to buy not one but two different companies and pick up 210 employees in the process.

The Morristown, NJ-based Capsugel said Monday it was acquiring Xcelience, a specialized contract development and manufacturing organization based in Tampa, FL, with 170 employees. It also is buying Powdersize, a Quakertown, PA-based contract manufacturer with expertise in particle size reduction with 40 employees. Terms of the two deals were not provided.

In an emailed statement, Amit Patel, president of Capsugel Dosage Form Solutions, said that Xcelience will enhance Capsugel's late-stage clinical-trial manufacturing and supply capabilities, and add specialized development and commercial manufacturing capabilities, including microdosing, multiparticulates, capsule-filling and tableting.

"In addition, Xcelience's infrastructure in Tampa supports the handling of highly potent and controlled substances, complementing Capsugel's specialized handling capabilities at its pharmaceutical dosage-form sites in the U.S., France, and the U.K.," Patel said. "Powdersize's micronization capabilities augment Capsugel's formulation design services and premier bioavailability enhancement platform."

Capsugel has been beefing up its global operations. In July, it announced a 40,000-square-foot expansion at a capsule production plant in Edinburgh, Scotland, that will more than double its capacity. That project will increase its liquid- and semisolid-fill hard capsule manufacturing capacity for drug products containing high-potency active pharmaceutical ingredients and add to the technology platforms the facility offers, like spray drying.

- here's the release

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.